Fecal transplant to boost new biologic treatment for ulcerative colitis
Part of Digestive system clinical trials.
This trial tests whether fecal microbiota transfer (a stool-based therapy) can improve outcomes when added to starting a new biologic medicine for ulcerative colitis. It compares fecal transplant versus placebo (a sham treatment) to see if symptoms and inflammation improve faster or more strongly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to under 75, and you can sign consent
- You have a confirmed ulcerative colitis diagnosis, with active disease currently (doctor-scored severity and scope findings)
- Your doctor is starting a biologic for you (vedolizumab or ustekinumab) and you are either biologic-naive or have failed certain other treatments
- You are not currently hospitalized for severe ulcerative colitis, and you don’t have signs of complications like a perforation or toxic megacolon
- In the last 4 weeks, you have not had C. difficile or other intestinal infections (and no recent diarrhea infection treatments)
- You can follow study rules, including stopping certain medicines/therapies and not having fecal transplant in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a stool transplant (fecal microbiota transplantation) can help manage active ulcerative colitis. You would receive a transplant from a healthy donor to see if it improves your symptoms.
This trial tests whether fecal microbiota transplantation (FMT) can safely and effectively treat mild to moderate ulcerative colitis over the long term. FMT involves transferring stool from a healthy donor to restore a healthy balance of gut bacteria.
This trial tests if a fecal transplant combined with dietary changes can help control symptoms in people with active ulcerative colitis who haven't responded well to standard treatments or advanced therapies.
This trial studies whether transferring healthy stool bacteria into the gut (fecal microbiota transplantation, or FMT) can improve symptoms in children with ulcerative colitis. It may help by changing gut bacteria, especially for children who are newly diagnosed or who didn’t respond to standard treatments.
This trial tests whether transplanting stool bacteria into the colon (fecal microbiota transplantation) can improve ulcerative colitis symptoms in people with active, moderate to severe disease. If you qualify, the study team will also check that it’s safe for you and that you can safely undergo a scope exam.
This trial tests whether one or multiple fecal transplants from a healthy donor can help treat both a recurring C. diff infection and active ulcerative colitis. It aims to find the best schedule for the procedure.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.